Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Effect of fluoxetine on weight reduction in obese patients
Obesity is one of the most important health problems , which many people suffer from it . As a chronic disease , it is a precipitating factor for many medical conditions like hypertension , diabetes mellitus , hyperlipidemia , coronary artery disease , sleep apnea syndrome and some malignancies ( breast , uterus , prostate and colon carcinoma ) . With attention to this fact that obesity is an independent risk factor associated with significant increase in morbidity and mortality , treatment of overweight individuals is very important . One of the medications for short-term weight loss is fluoxetin . In this clinical trial study , fluoxetin effect on weight loss induction during 8 weeks was investigated . 201 cases with BMI between 25–42 were selected r and omly ( 113 female and 88 male ) and all received fluoxetine ( 40 mg daily ) for 8 weeks . Measurement was carried out after the 4th and 8th week of administration and 4 weeks after end of treatment . Management of 9 cases ( 4 due to weight gain and 5 due to headache ) were discontinued after 4 weeks of treatment . Data assessment s were performed using t-test and SPSS program . Mean body weight at first visit was 89.32±13.30 kg . At the 4th , 8th week of treatment and 4 weeks after study , the mean body weight of cases reached 86.09±13.27 ( p=0.00 ) , 82.69±11.31 ( p=0.00 ) and 81.97±13.26 ( p=0.00 ) respectively . Mean BMI at first visit was 34.90±5.20kg/m2 . At 4th , 8th weeks of treatment it was 33.72±5.20kg/m2 and 32.40±5.18kg/m2 respectively . Mean weight loss at 4th and 8th weeks of treatment was 3.24 kg and 6.67 kg respectively without any weight gain at the end of the 4th week after discontinuation of the drug . Fluoxetine is an effective , well-tolerated and relatively safe drug for short-term treatment of obesity
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .